Treatment of gliomatosis cerebri with temozolomide: A retrospective study of the AINO (Italian Association for Neuro-Oncology)

被引：0
|
作者：
Soffietti, R.
Ruda, R.
Laguzzi, E.
Buttolo, L.
Pace, A.
Carapella, C.
Riva, M.
Salvati, M.
Silvani, A.
Caroli, M.
机构：
[1] Univ Torino, Turin, Italy
[2] San Giovanni Battista Hosp, Turin, Italy
[3] Gen Hosp Brescia, Brescia, Italy
[4] Regina Elena Inst Canc Res, Rome, Italy
[5] Osped Niguarda Ca Granda, Milan, Italy
[6] Neurol Inst, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2033
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TEMOZOLOMIDE (TMZ) 1 WEEK ON/1 WEEK OFF AS INITIAL TREATMENT FOR HIGH RISK LOW GRADE OLIGODENDROGLIAL TUMORS: A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY
    Pellerino, A.
    Franchino, F.
    Pace, A.
    Carapella, C.
    Dealis, C.
    Caroli, M.
    Faedi, M.
    Bomprezzi, C.
    Ruda, R.
    Soffietti, R.
    NEURO-ONCOLOGY, 2017, 19 : 21 - 21
  • [22] Bevacizumab and Fotemustine for Recurrent Glioblastoma - Final Results of a Multicenter Phase II Study of AINO (Italian Association of Neuro-Oncology)
    Trevisan, E.
    Ruda, R.
    Bertero, L.
    Bosa, C.
    Ciccone, G.
    Morra, I.
    Fabrini, M. G.
    Lolli, I.
    Soffietti, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S576 - S576
  • [23] The role of temozolomide in neuro-oncology
    C. Marosi
    memo - Magazine of European Medical Oncology, 2010, 3 (Suppl 3) : 15 - 17
  • [24] Final results of depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO)
    Padovan, M.
    Eoli, M.
    Pellerino, A.
    Rizzato, S.
    Caserta, C.
    Simonelli, M.
    Michiara, M.
    Caccese, M.
    Anghileri, E.
    Finocchiaro, G.
    Zagonel, V.
    Ruda, R.
    Lombardi, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S399 - S400
  • [25] The role of temozolomide in neuro-oncology
    Marosi, C.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2010, 3 : 15 - 17
  • [26] PHASE II TRIAL OF BEVACIZUMAB WITH FOTEMUSTINE IN RECURRENT GLIOBLASTOMA: FINAL RESULTS OF A MULTICENTER STUDY OF AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY)
    Soffietti, Riccardo
    Trevisan, Elisa
    Ruda, Roberta
    Bertero, Luca
    Bosa, Chiara
    Fabrini, Maria Grazia
    Lolli, Ivan
    NEURO-ONCOLOGY, 2011, 13 : 56 - 57
  • [27] Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology).
    Soffietti, R.
    Trevisan, E.
    Ruda, R.
    Bertero, L.
    Bosa, C.
    Fabrini, M. G.
    Lolli, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Clinical, Imaging and Neurogenetic Features of Patients with Gliomatosis Cerebri Referred to a Tertiary Neuro-Oncology Centre
    Doig, David
    Thorne, Lewis
    Rees, Jeremy
    Fersht, Naomi
    Kosmin, Michael
    Brandner, Sebastian
    Jager, Hans Rolf
    Thust, Stefanie
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (02):
  • [29] Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
    Padovan, Marta
    Eoli, Marica
    Pellerino, Alessia
    Rizzato, Simona
    Caserta, Claudia
    Simonelli, Matteo
    Michiara, Maria
    Caccese, Mario
    Anghileri, Elena
    Cerretti, Giulia
    Ruda, Roberta
    Zagonel, Vittorina
    Lombardi, Giuseppe
    CANCERS, 2021, 13 (11)
  • [30] Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series
    Anghileri, Elena
    Schettino, Carla
    Pollo, Bianca
    Farinotti, Mariangela
    Silvani, Antonio
    Paterra, Rosina
    Patane, Monica
    DiMeco, Francesco
    Bruzzone, Maria Grazia
    Eoli, Marica
    Cuccarini, Valeria
    NEUROLOGICAL SCIENCES, 2020, 41 (08) : 2111 - 2120
12345